MAN2B1 sirna

MAN2B1 siRNA (Human)

Cat. Num. AAA8229821

• Gene Names: MAN2B1; MANB; LAMAN
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: MAN2B1; MAN2B1 siRNA (Human); LAMAN; MANB; Lysosomal alpha-mannosidase; Laman; Lysosomal acid alpha-mannosidase; Mannosidase alpha class 2B member 1; Mannosidase alpha-B; MAN2B1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: MAN2B1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1011

• Applicable Applications for MAN2B1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MAN2B1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for MAN2B1 sirna

siRNA to inhibit MAN2B1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 51873064
• NCBI GeneID: 4125
• NCBI Accession #: NP_000519.2
• NCBI GenBank Nucleotide #: NM_000528.3
• UniProt Accession #: O00754; O15330; Q16680; Q93094; Q9BW13; G5E928
• Molecular Weight: 113,616 Da
• NCBI Official Full Name: lysosomal alpha-mannosidase isoform 1
• NCBI Official Synonym Full Names: mannosidase, alpha, class 2B, member 1
• NCBI Official Symbol: MAN2B1
• NCBI Official Synonym Symbols: MANB; LAMAN
• NCBI Protein Information: lysosomal alpha-mannosidase
• UniProt Protein Name: Lysosomal alpha-mannosidase
• UniProt Gene Name: MAN2B1
• UniProt Synonym Gene Names: LAMAN; MANB; Laman
• UniProt Entry Name: MA2B1_HUMAN

NCBI Description

This gene encodes an enzyme that hydrolyzes terminal, non-reducing alpha-D-mannose residues in alpha-D-mannosides. Its activity is necessary for the catabolism of N-linked carbohydrates released during glycoprotein turnover and it is member of family 38 of glycosyl hydrolases. The full length protein is processed in two steps. First, a 49 aa leader sequence is cleaved off and the remainder of the protein is processed into 3 peptides of 70 kDa, 42 kDa (D) and 13/15 kDa (E). Next, the 70 kDa peptide is further processed into three peptides (A, B and C). The A, B and C peptides are disulfide-linked. Defects in this gene have been associated with lysosomal alpha-mannosidosis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Mar 2010]

Uniprot Description

MAN2B1: Necessary for the catabolism of N-linked carbohydrates released during glycoprotein turnover. Cleaves all known types of alpha-mannosidic linkages. Defects in MAN2B1 are the cause of lysosomal alpha- mannosidosis (AM). AM is a lysosomal storage disease characterized by accumulation of unbranched oligosaccharide chains. This accumulation is expressed histologically as cytoplasmic vacuolation predominantly in the CNS and parenchymatous organs. Depending on the clinical findings at the age of onset, a severe infantile (type I) and a mild juvenile (type II) form of alpha-mannosidosis are recognized. There is considerable variation in the clinical expression with mental retardation, recurrent infections, impaired hearing and Hurler- like skeletal changes being the most consistent abnormalities. Belongs to the glycosyl hydrolase 38 family.

Protein type: Glycan Metabolism - other glycan degradation; EC 3.2.1.24; Hydrolase

Chromosomal Location of Human Ortholog: 19p13.2

Cellular Component: lysosome

Molecular Function: zinc ion binding; carbohydrate binding; alpha-mannosidase activity

Biological Process: mannose metabolic process; protein deglycosylation; protein modification process

Disease: Mannosidosis, Alpha B, Lysosomal